Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
Jerome Winegarden, Attending Physician and Hematology Oncology Fellowship Program Director at Trinity Health, reposted from American Society of Hematology on LinkedIn:
”ASH continues to show exceptional leadership by advocating for patients with blood diseases.
Standing up for science is not just a great tag line!
It really means something to the millions of people who suffer from blood cancers and blood related diseases.
I’m so proud to be an ASH member.”
Quoting American Society of Hematology‘s post:
”Boldly Standing Up for Science.
2025 brought unprecedented political threats to scientific research, federal funding, and access to care, but hematology thrived.
Through the hashtag Fight 4 Hematology campaign, the Society stepped up to expand research funding and training opportunities, lead impassioned advocacy efforts, and amplify the voices of clinicians, researchers, and patients.
ASH is proud to serve hematologists who are dedicated to conquering blood diseases and improving the lives of patients around the world.
Thank you for being an ASH member and helping to make 2025 such a success!
View the 2025 ASH Annual Report.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events